HPV Vaccine Hesitancy Among Indiana Youth With Cancer and Blood Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

176 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-04

Study Completion Date

2022-07-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For the identified groups of patients (survivors of childhood cancer and youth with sickle cell disease) the investigators want to better understand the barriers to, and facilitators of, HPV vaccination. Through HCP interviews the investigators will also assess both attitudinal and logistical obstacles to HPV vaccination. Some subspecialty HCPs may believe, for instance, that it is the primary care provider's responsibility to vaccinate or they may be unfamiliar with the requirement to enter vaccination data into CHIRP. Also, in some cases HPV vaccine may not be readily available in subspecialty clinic locations and/or subspecialty HCPs may not be Vaccines for Children (VFC) providers. Participants: the investigators will focus on two patient groups: survivors of childhood cancer, which includes children aged 9-21 years who have completed active therapy for cancer and are eligible for vaccination, and sickle cell disease, which includes children aged 9-21 years with a diagnosis of sickle cell disease. The investigators will recruit parents of children aged 9-21 years and older adolescents aged 18-21 years. For pediatric patients, the investigators selected a lower age of 9 years because HPV vaccine is licensed down to 9 years of age, and an upper limit of 21 years, as that is considered the upper bound of adolescence by the American Academy of Pediatrics. For patients 9-17 years of age, only parents will be interviewed by video or phone because parents are the vaccine decision-makers. For patients 18-21 years of age, the investigators will interview both young adults and their parents, because, while the young adult has legal decision-making capacity, in reality, the decision is frequently made jointly by the young adult and parent, and older adolescents are frequently unwilling to go against their parents' wishes. All research procedures will be conducted in English. Participants will be excluded if they have an intellectual disability or severe medical illness such that they are unable to consent or to understand the questions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Pilot Study Comparing the Effectiveness of Campus Intervention to Increase HPV Vaccine Rate Among College Aged Men

NCT02508701

Human Papilloma Virus, Male

TERMINATED NA

Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers

NCT01087164

Human Papillomavirus Infection

UNKNOWN NA

Parent-son-provider Decision-making About HPV Vaccination

NCT01284374

Human Papillomavirus Vaccination

COMPLETED

Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine

NCT02546752

Human Papilloma Virus Infection Type 11 Human Papilloma Virus Infection Type 16 Human Papilloma Virus Infection Type 18 +2 more

COMPLETED EARLY_PHASE1

HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts

NCT02551887

Human Papilloma Virus Infection Type 11 Human Papilloma Virus Infection Type 16 Human Papilloma Virus Infection Type 18 +4 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Papilloma Virus Vaccine Hesitancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient Focused Interviews

Interviews

Intervention Type BEHAVIORAL

We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.

Caregiver Focused Interviews

Interviews

Intervention Type BEHAVIORAL

We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.

Healthcare Provider Focused Interviews

Interviews

Intervention Type BEHAVIORAL

We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interviews

We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 9-21 years of age for patients with sickle cell disease or cancer.
* Caregiver of patient with sickle cell disease or cancer.
* Healthcare provider of patient with sickle cell disease or cancer.